Associations of CYP1A2 Polymorphisms with the Risk Haplotypes in Lung Cancer in the Slovak Population
Phase I enzymes, including cytochrome P450, family 1, subfamily A, and polypeptide 2 (CYP1A2), are involved in the activation of carcinogens to reactive intermediates that are capable of binding covalently to DNA to form DNA adducts, potentially initiating the carcinogenic process. The aim of present study was to investigate the association of CYP1A2 gene polymorphisms and haplotypes with lung cancer risk. A case-control study was carried out on 105 lung cancer patients and 189 controls. To investigate three CYP1A2 polymorphisms: rs2472299, rs2470890, rs11072508 we used a high resolution melting analysis. We found significant allele associations (rs2470890 and rs2422299) with lung cancer risk. We searched for meaningful associations for all variants in the dominant, recessive, and additive genetic models. Genotype associations in the recessive model were of marginal significance for the same single nucleotide polymorphisms. A haplotype analysis included five variants with the frequency higher than 1 %. The haplotype “acc”, present with the highest frequency, was associated with increased lung cancer risk (38.7 % vs. 31.5 %; OR 1.38; 95 %CI 0.95–2.01). On the contrary, rare haplotype “gtc” was significantly associated with decreased lung cancer risk in the Slovak population. In conclusion, the present study identified the risk alleles and haploid genotype associations of the CYP1A2 gene in lung cancer.
KeywordsCarcinogenesis Cytochrome P450 Genotyping Haplotypes CYP1A2 Lung cancer Polymorphisms CYP1A2
This work was supported by grants: the MZ SR 2012/25-UKMA-2, APVV-0412-11, and VEGA 1/0336/12.
Conflicts of Interest
The authors declare no conflicts of interest in relation to this article.
- Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, Goldin LR, Wacholder S, Welch R, Burdette L, Chanock SJ, Bertazzi PA, Tucker MA, Caporaso NE, Chatterjee N, Bergen AW, Landi MT (2009) Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One 4, e5652. doi: 10.1371/journal.pone.0005652 CrossRefPubMedPubMedCentralGoogle Scholar
- The 1000 Genomes Project Consortium (2012) Nature 491:56–65Google Scholar